Olaparib (Lynparza)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: PARP (poly-ADP (adenosine diphosphate)–ribose polymerase) inhibitor. PARP participates in the alternative base-excision repair pathway that helps to repair single-strand DNA breaks. PARP is involved in normal cellular homeostasis processes during DNA transcription and cell cycle regulation. By inhibiting PARP1, PARP2, and PARP3, olaparib leads to the accumulation of single-strand breaks. In patients with a concurrent BRCA1/BRCA2 mutation, in which there are also defects in homologous recombination double strand DNA repair, this inhibition of PARP enzymatic activity and formation of the PARP-DNA complex can lead to irrecoverable DNA damage and cell death.[1][2][3] [4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.[1]

Diseases for which it is established

Diseases for which it is used

Patient drug information

History of changes in FDA indication

gBRCAm Breast cancer

Ovarian cancer - PARTIALLY WITHDRAWN

gBRCAm Pancreatic cancer

Prostate cancer

  • 2020-05-19: Approved for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (New disease entity; based on PROfound)
  • 2023-05-31: Approved with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test. (Based on PROpel)

History of changes in EMA indication

gBRCAm Breast cancer

  • 2019-04-08: Indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy
  • 2022-08-02: Indicated as monotherapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
  • 2022-08-02: Indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

Ovarian cancer

  • 2014-12-16: Initial marketing authorization as Lynparza. Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. (Based on Study 19)
  • 2019-06-12: Indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • 2020-03-11: Indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
  • 2022-12-16: Indication withdrawn as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum based chemotherapy.

Pancreatic cancer

  • 2020-07-03: Indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. (Based on POLO)

Prostate cancer

  • 2020-03-11: Indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
  • 2022-12-16: Indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. (Based on PROpel)

History of changes in Health Canada indication

  • 2016-04-29: Initial notice of compliance with conditions
  • 2018-05-02: Conditions were met
  • 2018-05-04: Notice of compliance with conditions as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed (PSR) BRCA wild type high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
  • 2022-07-27: Notice of compliance with conditions for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.

History of changes in PMDA indication

Breast cancer

  • 2018-01-19: New approval for the maintenance treatment of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy.
  • 2018-07-02: New additional indication for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy.
  • 2022-08-24: New indication and a new dosage for the postoperative adjuvant treatment of BRCA mutation-positive and HER2-negative breast cancer with a high risk of recurrence.

Ovarian cancer

  • 2019-06-18: New indication for maintenance treatment of BRCA mutation-positive ovarian cancer in patients who have received first chemotherapy.
  • 2020-12-25: New indication and new dosage for the maintenance treatment of homologous recombination deficiency (HRD)-positive ovarian cancer in patients who have received first chemotherapy including treatment with bevacizumab.

Pancreatic cancer

  • 2020-12-25: new indication and a new dosage for maintenance therapy of unresectable BRCA mutation-positive pancreatic cancer after chemotherapy including treatment with platinum-based antineoplastic drugs.

Prostate cancer

  • 2020-12-25: New indication and new dosage for the treatment of metastatic, BRCA mutation-positive, castration-resistant prostate cancer.

Also known as

  • Code names: AZD-2281, KU-0059436
  • Brand name: Lynparza, Olanib, Olaparix

References

  1. ↑ 1.0 1.1 1.2 Olaparib (Lynparza) package insert
  2. ↑ Olaparib (Lynparza) package insert (locally hosted backup)
  3. ↑ Lynparza manufacturer's website
  4. ↑ Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34. Epub 2009 Jun 24. link to original article PubMed
  5. ↑ Olaparib (Lynparza) patient drug information (Chemocare)
  6. ↑ Olaparib (Lynparza)patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Olaparib_(Lynparza)&oldid=84721"